US FDA Revisits PD-L1 Biomarker In Gastric, Esophageal Cancers

 
• By Bridget Silverman
  
esophageal cancer
Labeling for PD-1 inhibitors in esophageal cancer could be changed. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers